Bonnie W. Nannenga-Combs, Ph.D. is a director in Sterne Kessler’s Biotechnology & Chemical Practice Group. Bonnie represents clients in various stages of development and commercialization of life science therapeutics, such as gene therapy, RNA therapies, antisense technologies, biologics, therapeutic antibodies, cell therapy, vaccines, diagnostics, small and large molecule formulations, and nucleic acid delivery. She counsels domestic and international clients on patent procurement, clearance strategies, and management of complex worldwide patent portfolios. Bonnie’s expertise includes developing exclusivity strategies for companies with therapies targeting genetic diseases, including orphan and rare diseases, and vaccines for bacterial and viral diseases.

Bonnie counsels clients during IP due diligence for asset acquisition and M&A. She is particularly skilled in identifying portfolio strengths and weaknesses, which helps clients assess IP portfolio valuation and risk management. Bonnie excels at building relationships with clients to better understand each client’s unique IP needs, which is critical in assisting clients to achieve their business goals such as executing strategic partnerships and M&A transactions, IP portfolio building, IP risk management, raising funds, and going public.

Bonnie is active in the firm’s Pro Bono Practice. She works with pro bono clients to prepare and prosecute patents that can be used to help advance economic, social, and cultural rights.

Bonnie earned her Ph.D. in molecular & cellular biology at Baylor College of Medicine. She received her J.D. from Seattle University School of Law and a B.S. in biology from Hope College.

Technical Publications

  • “Augmented Cancer Resistance and DNA Damage Response Phenotypes in PPM1D Mice.” Bonnie Nannenga, Xiongbin Lu, Melissa Dumble, Marc Van Maanen, Thuy-Ai Nguyen, Frances Kittrell, Daniel Medina,T. Rajendra Kumar, and Lawrence A. Donehower. Molecular Carcinogenesis 2006.
  • “Dual roles for the phosphatase PPM1D in regulating progesterone receptor function. ” Proia DA, Nannenga BW, Donehower LA, Weigel NL. J Biol Chem. March 2006.
  • “PPM1D dephosphorylates Chk1 and p53 and abrogates cell cycle checkpoints. ” Xiongbin Lu, Bonnie Nannenga, Lawrence A. Donehower. Genes & Development 2005.
  • “The p53-Induced Oncogenic Phosphatase Ppm1d Interacts with Uracil DNA Glycosylase and Suppresses Base Excision Repair.” X. Lu, D. Bocangel, B. Nannenga, H. Yamaguchi, E. Appella and L. Donehower. Molecular Cell 2004.
  • “Inactivation of the Wip1 Phosphatase Inhibits Mammary Tumorigenesis through p38 MAPK-Mediated Activation on the p16Ink4a-p19Arf Tumor Suppressor Pathway.” D. Bulavin, C. Phillips, B. Nannenga, O. Timofeev, L. Donehower, C. Anderson, E. Appella, A. Fornace Jr. Nature Genetics 2004.
  • “Mice Deficient for Wild-Type p53-Induced Phosphatase Gene (Wip1) Exhibit Defects in Reproductive Organs, Immune Function, and Cell Cycle Control.” J. Choi, B. Nannenga, O. Demidov, D. Bulavin, A. Cooney, C. Brayton, Y. Zhang, I. Mbawuike, A. Bradley, E. Appella, and L. Donehower. Molecular and Cellular Biology 2002.
  • “Enhanced Liver Cell Mutations in Trematode-Infected Big Blue Transgenic Mice. ” J. Gentile, G. Gentile, B. Nannenga, M. Johnson, H. Blankespoor, R. Montero. Mutation Research 1998.

  • Profiles in Diversity Journal, “Women Worth Watching® in STEM” (2021)

  • B.A., Baylor College of Medicine, cum laude
  • B.A., Molecular and Cellular Biology, Baylor College of Medicine
  • B.A., Biology, Baylor College of Medicine, cum laude

  • District of Columbia
  • United States Patent & Trademark Office

Speaking Engagement

2023 Focus on Pharma

Washington, DC, April 14, 2023 8:30 AM - 6:00 PM EST

Speaking Engagement

Comprehensive and Effective IP Due Diligence

Virtual, June 17, 2021 12:20 PM - 1:10 PM EST

Related News & Insights

From Bonnie W. Nannenga-Combs, Ph.D.

Press Release

June 29, 2021

Directors Gillentine and Nannenga-Combs Deemed “Women Worth Watching® in STEM”

Sterne, Kessler, Goldstein & Fox

Client Alert

July 7, 2020

IP Hot Topic: Patent Prosecution Tool Kit

Carla Ji-Eun Kim

Reports

July 7, 2020

Patent Prosecution Tool Kit

Sterne, Kessler, Goldstein & Fox Multiple Authors

Bylined Articles

July 7, 2020

1.132 Declarations for Traversing Rejections

Sterne, Kessler, Goldstein & Fox Multiple Authors

Bylined Articles

July 7, 2020

Federally Funded Inventions and Compliance with the Bayh-Dole Act

Sterne, Kessler, Goldstein & Fox Bonnie W. Nannenga-Combs, Ph.D., John M. Covert

Books and Chapters

October 1, 2019

U.S. Chemical Patent Law: A Practical Guide

Bloomberg Law Multiple Authors

Press Release

October 1, 2019

Sterne Kessler Attorneys Author U.S. Chemical Patent Law

Sterne, Kessler, Goldstein & Fox P.L.L.C

Client Alert

June 19, 2018

Updated Bayh-Dole Regulations Increase Certain Risks of Losing Title to Federally Funded Inventions

Bonnie W. Nannenga-Combs, Ph.D., John M. Covert

Reports

June 28, 2017

Patent Prosecution Tool Kit

Multiple Authors

In the News

April 6, 2016

MIP Africa Roadshow 2016 - Live Updates

Managing Intellectual Property

Bylined Articles

March 17, 2016

The Impact of Reformulation Strategies on Pharmaceuticals, Biologics

BioProcess Online Multiple Authors

In the News

January 1, 2016

Sterne Kessler Directors Featured in Washington Business Journal’s "People on the Move"

Washington Business Journal & Patent, Trademark & Copyright Journal